Once-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b Study
Main Article Content
Javier Alonso-Llamazares
Neal Bhatia
Alim Devani
Michael Bukhalo
Zoe Draelos
Melinda Gooderham
Steve Kempers
Leon Kircik
Kim Papp
David Pariser
Marina Sankeva
Rodney Sinclair
Matthew Zirwas
Amy Feng
Patrick Burnett
Robert Higham
David Berk
Keywords
roflumilast, foam, itch, psoriasis
Abstract
N/A
References
2. Elewski B, et al. J Eur Acad Dermatol Venereol 2019;33:1465-1476.
3. Dopytalska K, et al. Reumatologia 2018;56:392-398.
4. Blakely K, Gooderham M. Psoriasis 2016;6:33-40.
5. Lebwohl MG, et al. N Engl J Med 2020;383:229-239
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.